Marquis Who’s Who Honors Paul Peter Tak, MD, PhD, FMedSci for Expertise in Medicine and Research
https://www.24-7pressrelease.com/press-release/528367/marquis-whos-who-honors-paul-peter-tak-md-phd-fmedsci-for-expertise-in-medicine-and-research
ASCO 2025: Candel CEO shares Phase 3 prostate cancer data on off-the-shelf immunotherapy.
At the 2025 ASCO Annual Meeting in Chicago (May 30–June 3), Candel Therapeutics presented the results from its pivotal Phase 3 trial of CAN‑2409 (aglatimagene besadenovec) combined with valacyc…
Bridging clinical practice and biotech.
Former GSK immunology leader Paul Peter Tak, MD PhD FMedSci, now President & CEO of Candel Therapeutics, sits down with Mike Rea (CEO of IDEA Pha…
The Mindful Leadership Podcast
In this inaugural Season 3 episode, Dr. Paul Peter Tak, MD PhD FMedSci, shares his journey from rheumatologist and academic to biotech leader, framed by a central p…
The Studio at Kendall: Candel and IDEA Pharma CEOs on mindset and communication in biotech innovation
The Studio at Kendall: Candel and IDEA Pharma CEOs on mindset and communication in biotech innovation.
https://www.linkedin.com/posts/biotechtv_%F0%9D%90%93%F0%9D%90%A1%F0%9D%90%9E-%F0%9D%90%…
CAN-3110: Experimental treatment of glioblastoma.
In this interview, Paul Peter Tak, President & CEO of Candel Therapeutics, offers a deep dive into the company’s viral immunotherapy platform, CA…
